A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (Pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed IM therapy.

被引：0
|
作者：
Cortes, J
Garcia-Manero, G
O'Brien, S
Hernandez, I
Rackoff, W
Faderl, S
Thomas, D
Ferrajoli, A
Talpaz, M
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Johnson & Johnson Pharmaceut Res & Dev, LLC, Titusville, NJ USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1011
引用
收藏
页码：289A / 289A
页数：1
相关论文
共 50 条
  • [31] Delayed achievement of molecular responses is associated with increased risk of progression among patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) treated with imatinib (IM).
    Quintas-Cardama, Alfonso
    Kantarjian, HagopM.
    Jones, Dan
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Shan, Jenny
    Ravandi, Farhad
    Wierda, William G.
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 132A - 132A
  • [32] Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL)
    Brummendorf, T. H.
    Cortes, J. E.
    Kantarjian, H.
    Gambacorti-Passerini, C.
    Baccarani, M.
    Kim, D.
    Zaritskey, A.
    Navarro, J.
    Rapoport, A.
    Dorlhiac-Llacer, P. E.
    Milone, J.
    Zanichelli, M.
    Besson, N.
    Leip, E.
    Kelly, V.
    Khoury, H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase
    Kiguchi, Toru
    Tauchi, Tetsuzo
    Ito, Yoshikazu
    Miyazawa, Keisuke
    Kimura, Yukihiko
    Ohyashiki, Kazuma
    LEUKEMIA RESEARCH, 2009, 33 (03) : 506 - 508
  • [34] The predictive value of early molecular response by relative risk in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from the phase 3 DASISION trial
    Stegelmann, F.
    Shah, N. P.
    Saglio, G.
    Hochhaus, A.
    Bilmes, R.
    Li, L.
    Cortes, J. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 40 - 40
  • [35] Effect of Nilotinib (NIL) on Molecular Response in Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) Patients (pts) with a Suboptimal Molecular Response to Imatinib (IM)-ENABL Study Update
    Ailawadhi, Sikander
    Miller, Carole B.
    Jillella, Anand P.
    Koshy, Nebu
    Tudor, Brian
    Akard, Luke P.
    Ericson, Solveig G.
    Lin, Felice P.
    Radich, Jerald P.
    DeAngelo, Daniel J.
    BLOOD, 2011, 118 (21) : 1193 - 1193
  • [36] BOSUTINIB FOR THIRD-LINE TREATMENT OF CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) FOLLOWING RESISTANCE OR INTOLERANCE TO IMATINIB (IM) AND DASATINIB (D)
    Gambacorti-Passerini, C.
    Cortes, J.
    Zaritskey, A.
    Bullorsky, E.
    Navarro, J.
    Khoury, H.
    Besson, N.
    McMullan, T.
    Arkin, S.
    Bruemmendorf, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 57 - 58
  • [37] Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).
    Khoury, H. J.
    Kim, D.
    Zaritskey, A.
    Apperley, J.
    Besson, N.
    Volkert, A.
    Wang, J.
    Arkin, S.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Darbepoetin alfa (Aranesp™) for anemia during imatinib mesylate (Gleevec™) therapy for chronic phase chronic myeloid leukemia (CML).
    Quintas-Cardama, A
    Ault, P
    Kantarjian, H
    O'Brien, S
    Cabanillas, M
    Rios, MB
    Verstovsek, S
    Talpaz, M
    Cortes, J
    BLOOD, 2003, 102 (11) : 312B - 312B
  • [39] Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study
    Kantarjian, H.
    Shah, N. P.
    Hochhaus, A.
    Cortes, J. E.
    Shah, S.
    Ayala, M.
    Moiraghi, B.
    Bradley-Garelik, M.
    Zhu, C.
    Baccarani, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [40] Dasatinib (SPRYCEL®) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (Im-r) or -intolerant (Im-i).
    Martinelli, Giovanni
    Hochhaus, A.
    Coutre, S.
    Apperley, J. F.
    Shah, N.
    Gollerkeri, A.
    Agarwal, P.
    Ottmann, O. G.
    BLOOD, 2006, 108 (11) : 224A - 224A
12345